Intech Investment Management LLC Makes New $228,000 Investment in Astria Therapeutics, Inc. (NASDAQ:ATXS)

Intech Investment Management LLC acquired a new stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 20,665 shares of the biotechnology company’s stock, valued at approximately $228,000.

A number of other institutional investors have also recently made changes to their positions in ATXS. Nantahala Capital Management LLC purchased a new stake in Astria Therapeutics during the second quarter valued at approximately $6,142,000. Vanguard Group Inc. lifted its position in Astria Therapeutics by 23.4% during the first quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock valued at $35,693,000 after purchasing an additional 480,184 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in Astria Therapeutics during the second quarter valued at about $2,561,000. Millennium Management LLC lifted its position in shares of Astria Therapeutics by 13.5% during the 2nd quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company’s stock valued at $16,763,000 after buying an additional 218,518 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Astria Therapeutics by 1,043.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 146,158 shares of the biotechnology company’s stock valued at $1,330,000 after acquiring an additional 133,379 shares during the period. Hedge funds and other institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Stock Down 3.8 %

NASDAQ ATXS opened at $9.75 on Friday. The firm has a market cap of $550.19 million, a PE ratio of -4.67 and a beta of 0.67. Astria Therapeutics, Inc. has a 52 week low of $4.87 and a 52 week high of $16.90. The company has a 50 day moving average price of $10.98 and a 200 day moving average price of $10.64.

Analysts Set New Price Targets

ATXS has been the topic of several recent analyst reports. Wedbush restated an “outperform” rating and set a $22.00 price objective on shares of Astria Therapeutics in a research report on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a research note on Thursday, November 14th. Evercore ISI raised shares of Astria Therapeutics to a “strong-buy” rating in a report on Wednesday, August 14th. Finally, Oppenheimer raised their target price on shares of Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Thursday, November 14th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $25.60.

Astria Therapeutics Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.